China-based peripheral interventional device manufacturer Shanghai Easy-Flow Medical Tech Co., Ltd has reportedly raised “tens of millions” of renminbi in an angel financing round. The funding was led by Legend Capital, with participation from Shanghai Xinyue Jiupeng Enterprise Consulting Center. The proceeds will be allocated toward the research and development of Easy-Flow Medical’s peripheral interventional product pipelines.
Market Context and Company Background
According to Frost & Sullivan, the market for peripheral vascular interventional medical devices in China is estimated to be worth RMB 7.12 billion (USD 974.6 million). Imported products currently dominate this market, with the exception of arterial balloons and vena cava filters. Founded in 2021, Easy-Flow Medical is developing a rapamycin drug balloon for infra-knee vascular disease. Compared to paclitaxel coatings, rapamycin coatings offer superior anti-restenosis ability and safety. However, rapamycin’s hydrophilicity results in a shorter duration in the bloodstream and effective drug time.
Product Development and Future Outlook
Preliminary animal experiments have shown that Easy-Flow Medical’s rapamycin drug balloon has a longer duration in animal vascular tissues and continues to inhibit intimal hyperplasia. This suggests potential advantages over existing solutions. The company is expected to make multiple clinical filings or initiate clinical trials next year, marking a significant step forward in its development pipeline.-Fineline Info & Tech
